Nanocarry Therapeutics
Kadima-Tzoran, Israel· Est.
Nano‑engineered platform that delivers biologics across the BBB for brain cancers and CNS disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $5M
AI Company Overview
Nano‑engineered platform that delivers biologics across the BBB for brain cancers and CNS disorders.
OncologyCNS
Technology Platform
Bio‑engineered gold nanoparticles functionalized for receptor‑mediated transcytosis enable high‑efficiency delivery of antibodies and other biologics across the blood‑brain barrier.
Opportunities
The platform can unlock the $30‑40 bn CNS biologics market and enable rapid co‑development of brain‑penetrant therapies with pharma partners.
Risk Factors
Technical risk of achieving safe, scalable BBB delivery and regulatory uncertainties around nanoparticle‑based biologics.
Competitive Landscape
Few companies (e.g., Voyager Therapeutics, Neuropharm) address BBB delivery; Nanocarry differentiates through its gold‑nanoparticle, receptor‑mediated transcytosis platform and modular plug‑and‑play design.